trial summary · NCT06987383
Vibegron for ENergy Thinking and Resilience in Aging
Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity
Trial record from the TrialBase DB dataset, status RECRUITING, condition Obesity, sponsored by Wake Forest University Health Sciences. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Source record: https://clinicaltrials.gov/study/NCT06987383
Facts
| registry id | NCT06987383 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Obesity |
| sponsor | Wake Forest University Health Sciences |
| sponsor class | OTHER |
| enrollment | 40 |
| start date | 2026-10-27 |
| primary completion | 2028-07 |
| completion | 2028-07 |
| results posted | not reported |
Conditions
- Obesity
Interventions
- Vibegron
- Placebo
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.